Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1368

Sort by

Sort Order Select

Journal Articles

Resolving thromboinflammation

Stephen P. McAdoo, Neeraj Dhaun

Blood (2021) 137 (11): 1444–1446.

https://doi.org/10.1182/blood.2020010627

Published: 2021

Journal Articles

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Taylor J Chen, BS, Ye Shen, PhD, Cory Seth Bridges, BS, Chun Shik Park, PhD, Jacob J. Junco, PhD, Karen R. Rabin, MD PhD, H. Daniel Lacorazza, PhD

Blood (2019) 134 (Supplement_1): 3889.

https://doi.org/10.1182/blood-2019-129127

Published: 2019

Journal Articles

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Mick J.M. Van Eijs, MSc, Nicolette C. Notermans, MD PhD, Tom Würdinger, PhD, Monique C. Minnema, MD PhD

Blood (2019) 134 (Supplement_1): 3771.

https://doi.org/10.1182/blood-2019-124325

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Curcumin Enhances the Sensitivity of Bortezomib By Inhibiting NF-Κb in ABC Diffuse Large B-Cell Lymphoma Cells

Xiaolei Wei, PhD, Jialin Song, Yongqiang Wei, PhD, Hong Zeng, Weimin Huang, PhD, Jingxia Zheng, Ru Feng, MD

Blood (2019) 134 (Supplement_1): 5237.

https://doi.org/10.1182/blood-2019-127705

Published: 2019

Journal Articles

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

Christopher M Melén, MD, Magali Merrien, MSc, Agata Wasik, MSc, PhD, Kristina Sonnevi, MD PhD, Henna-Riikka Junlén, MD, Birger Christersson, MD PhD, Birgitta Sander, MD PhD Prof., Björn E Wahlin, MD PhD

Blood (2019) 134 (Supplement_1): 5487.

https://doi.org/10.1182/blood-2019-126693

Published: 2019

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

https://doi.org/10.1182/blood-2019-130784

Published: 2019

Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 5369.

https://doi.org/10.1182/blood-2019-129768

Published: 2019

Journal Articles

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Zhengchang He, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 5401.

https://doi.org/10.1182/blood-2019-131573

Published: 2019

Journal Articles

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Håkan Mellstedt, MD PhD Prof., Amineh Ghaderi, MSc, Johanna Aschan, MSc, Fariba Mozaffari, MSc,PhD, Ali Moshfegh, MSc,PhD, Birgitta Sander, MD PhD Prof., Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Mohammad Hojjat-Farsangi, MSc,PhD

Blood (2019) 134 (Supplement_1): 5312.

https://doi.org/10.1182/blood-2019-129773

Published: 2019

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Raoul Tibes, MD PhD, Diego Ferreira Coutinho, PhD, Michael Tuen Tuen, Xufeng Chen, PhD, Christina Glytsou, Ioannis Aifantis, Sergey Shmelkov, MD

Blood (2019) 134 (Supplement_1): 2559.

https://doi.org/10.1182/blood-2019-130931

Published: 2019

Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Mohammad Hojjat-Farsangi, MSc,PhD, Amineh Ghaderi, MSc, AmirHossein Daneshmanesh, MD PhD, Jemina Lehto, MSc, Ali Moshfegh, MSc,PhD, Parviz Kokhaei, MSc,PhD, Jan Vågberg, MSc,PhD, Elisabeth Olsson, MSc,PhD, Charlotta Löfberg, MSc,PhD, Charlotta Carina Norström, MSc,PhD, Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 2565.

https://doi.org/10.1182/blood-2019-126801

Published: 2019

Journal Articles

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Virginia Campos Silvestrini, BSc, MSc, Eduardo M Rego, MD PhD, Vitor Marcel Faca, PhD, João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 2689.

https://doi.org/10.1182/blood-2019-132129

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Blood (2019) 134 (Supplement_1): 2719.

https://doi.org/10.1182/blood-2019-131211

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Resolving thromboinflammation

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Curcumin Enhances the Sensitivity of Bortezomib By Inhibiting NF-Κb in ABC Diffuse Large B-Cell Lymphoma Cells

A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

HO-1 Promotes Resistance to EZH2 Inhibitor through the Prb-E2F Pathway: Corelated with the Conversion of Myelodysplastic Syndrome to Acute Myeloid Leukemia

ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only